LONDON, UK, 26 March 2007 - SkyePharma PLC (LSE: SKP; Nasdaq: SKYE) announces that the Paul Capital Refinancing and the Disposal of the Injectable Business have been completed. As such, the Placing of the New Ordinary Shares is no longer conditional and will raise GBP14.8m (net of costs). It is expected that admission and dealings in the new shares will commence at 8.00 a.m. today.
